Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 6, 1996, Pages 856-861

  Dingemanse, Jasper ^a,b   Guentert, Theodor ^a   Gieschke, Ronald ^a   Stabl, Max ^c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Clin Pharma Research Ltd   (Switzerland)

^c NONE

Author keywords

Ephedrine; Interaction; Moclobemide; Pharmacodynamics; Safety; Vital signs

Indexed keywords

4 [2 (4 CHLOROBENZAMIDO)ETHYL]MORPHOLINE 4 OXIDE; 4 CHLORO N [2 (3 OXOMORPHOLINO)ETHYL]BENZAMIDE; EPHEDRINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INSOMNIA; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC AGENTS; ADULT; BENZAMIDES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG SYNERGISM; EPHEDRINE; FEMALE; HEADACHE; HEART RATE; HUMANS; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; STIMULATION, CHEMICAL;

EID: 0029823896     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199612000-00017     Document Type: Article

References (31)

1. Blackwell B. Monoamine oxidase inhibitor interactions with other drugs. J Clin Psychopharmacol 1991;11:55-9.
2. Prisant LM, Carr AA. Over-the-counter drugs that may increase blood pressure. Postgrad Med 1989;86:205-8.
3. Wells DG, Bjorksten AR. Monoamine oxidase inhibitors revisited. Can J Anaesth 1989;36:66-74.
4. Potter WZ, Rudorfer MV, Manji H. The pharmacologic treatment of depression. N Engl J Med 1991;325:633-42.
5. Fitton A, Faulds D, Goa KL. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992;43:561-96.
6. Priest RG, Schmid-Burgk W. Moclobemide in the treatment of depression. Rev Contemp Pharmacother 1994;5:35-43.
7. Amrein R, Güntert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 1992;106:524-31.
8. Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S. Tyramine presser effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm 1988;26(suppl):57-71.
9. Wijnands S, Chang PC, Blauw GJ, et al. Potentiation of the presser effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers. J Psychopharmacol 1989;3:36-44.
10. Da Prada M, Zürcher G, Wüthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 1988;26(suppl):31-56.
11. Bieck PR, Antonin KH. Monoamine oxidase inhibition by tranylcypromine: assessment in healthy volunteers. Eur J Clin Pharmacol 1982;22:301-8.
12. Zimmer R, Gieschke R, Fischbach R, Gasic S. Interaction studies with moclobemide. Acta Psychiatr Scand 1990;82(suppl 360):84-6.
13. Drew CDM, Knight GT, Hughes DTD, Bush M. Comparison of the effects of D (-) ephedrine and L (+) pseudoephedrine on the cardiovascular and respiratory systems in man. Br J Clin Pharmacol 1978;6:221-5.
14. Empey DW, Young GA, Letley E, et al. Dose-response study of the nasal decongestant and cardiovascular effects of pseudoephedrine. Br J Clin Pharmacol 1980;9:351-8.
15. Kuitunen T, Kärkkäinen S, Ylitalo P. Comparison of the acute physical and mental effects of ephedrine, fenfluramine, phentermine and prolintane. Methods Find Exp Clin Pharmacol 1984;6:265-70.
16. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995;29:292-332.
17. Jauch R, Griesser E, Oesterhelt G, et al. Biotransformation of moclobemide in humans. Acta Psychiatr Scand 1990;82(suppl 360):87-90.
18. Geschke R, Koerner J, Eggers H. Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatography. J Chromatogr 1987;420:111-20.
19. Versiani M, Nardi AE, Figueira ILV, Stabl M. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase A, compared with other antidepressants and placebo. Acta Psychiatr Scand 1990;360:21-8.
20. Moll E, Neumann N, Schmid-Burgk W, Stabl M, Amrein R. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 1994;17(suppl 1):S74-87.
21. Coulter DM, Pillans PI. Hypertension with moclobemide. Lancet 1995;346:1032.
22. Chen DT, Ruch R. Safety of moclobemide in clinical use. Clin Neuropharmacol 1993;16(suppl 2):S63-8.
23. Bradley JG. Nonprescription drugs and hypertension: which ones affect blood pressure? Postgrad Med 1991;89:195-202.
24. Weiner N. Norepinephrine, epinephrine, and the sympathomimetic amines. In: Gilman A, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 7th ed. New York: Macmillan, 1985:169-70.
25. Franciosa JA, Conn JN. Hemodynamic effects of oral ephedrine given alone or combined with nitroprusside infusion in patients with severe left ventricular failure. Am J Cardiol 1979;43:79-85.
26. Astrup A, Toubro S, Cannon S, Hein P, Madsen J. Thermogenic, metabolic, and cardiovascular effects of a sympathomimetic agent, ephedrine: a double-blind placebo-controlled study. Curr Ther Res Clin Exp 1990;48:1087-100.
27. Elis J, Laurence DR, Mattie H, Pritchard BNC. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J 1967;2:75-8.
28. Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 1989;248:400-14.
29. Boakes AJ, Teoh PC, Barar FKS, Benedikter LT, Prichard BNC. Interaction between sympathomimetic amines and antidepressant agents in man. Br Med J 1973;1:311-5.
30. Gleiter CH, Mühlbauer B, Gradin-Frimmer G, Antonin KH, Bieck PR. Administration of sympathomimetic drugs with the selective MAO-A inhibitor brofaromine: effect on blood pressure. Drug Invest 1992;4:149-54.
31. Pickering G. Environmental changes and arterial pressure. In: Pickering G, ed. High blood pressure. London: Churchill, 1968:35-58.